Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIO-TECHNE CORPORATION

(TECH)
  Report
Delayed Quote. Delayed Nasdaq - 11/26 01:00:00 pm
473.47 USD   -0.73%
11/23BIO TECHNE : Annual Report FY 2021
PU
11/22Bio-Techne To Present At Upcoming Investor Conferences
PR
11/16INSIDER SELL : Bio-Techne
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
501.5(c) 489.63(c) 472.72(c) 476.97(c) 473.47(c) Last
279 098 224 152 255 888 216 995 114 941 Volume
+1.28% -2.37% -3.45% +0.90% -0.73% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 088 M - -
Net income 2022 236 M - -
Net cash position 2022 224 M - -
P/E ratio 2022 82,9x
Yield 2022 0,27%
Sales 2023 1 245 M - -
Net income 2023 276 M - -
Net cash position 2023 264 M - -
P/E ratio 2023 70,8x
Yield 2023 0,27%
Capitalization 18 605 M 18 605 M -
EV / Sales 2022 16,9x
EV / Sales 2023 14,7x
Nbr of Employees 2 600
Free-Float 99,4%
More Financials
Company
Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and... 
More about the company
Ratings of Bio-Techne Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BIO-TECHNE CORPORATION
11/23BIO TECHNE : Annual Report FY 2021
PU
11/22Bio-Techne To Present At Upcoming Investor Conferences
PR
11/16INSIDER SELL : Bio-Techne
MT
11/10BIO-TECHNE CORPORATION : Ex-dividend day for
FA
11/09Bio-Techne To Present At The Stifel 2021 Virtual Healthcare Conference
PR
11/08BIO-TECHNE CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL (form 10-Q)
AQ
11/08Asuragen Launches New Kit to Enable Broader Coverage of Gene Variants Linked to Cystic ..
PR
11/04Bio-Techne To Present At The Credit Suisse 30th Annual Healthcare Conference
PR
11/03Baird Adjusts Price Target on Bio-Techne to $548 From $522, Keeps Outperform Rating
MT
11/03Bio-Techne Announces Commercial Availability Of GMP-Grade Proteins From Dedicated GMP F..
PR
11/03Bio-Techne Announces Commercial Availability Of GMP-Grade Proteins From Dedicated GMP F..
CI
11/02Bio-Techne Posts Higher Fiscal Q1 Adjusted Profit, Sales
MT
11/02BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2022 RESULTS - Form 8-K
PU
11/02BIO-TECHNE CORP : Results of Operations and Financial Condition, Other Events, Financial S..
AQ
11/02Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q1 Revenue $257.7M
MT
More news
News in other languages on BIO-TECHNE CORPORATION
11/02Bio-Techne affiche un bénéfice ajusté et des ventes plus élevés au premier trimestre de..
11/02Earnings Flash (TECH) BIO-TECHNE CORPORATION annonce un chiffre d'affaires de 257,7 mil..
11/02Bio-Techne Corporation déclare un dividende pour le trimestre clos le 30 septembre 2021..
09/15Selon KeyBanc, le plan de Bio-Techne visant à doubler les ventes en cinq ans s'appuie s..
09/09VENTE D'INITIÉS : Bio-techne
More news
Analyst Recommendations on BIO-TECHNE CORPORATION
More recommendations
Stock Trading Strategies
BIO-TECHNE CORPORATION - 07/20
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart BIO-TECHNE CORPORATION
Duration : Period :
Bio-Techne Corporation Technical Analysis Chart | TECH | US09073M1045 | MarketScreener
Technical analysis trends BIO-TECHNE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 473,47 $
Average target price 532,91 $
Spread / Average Target 12,6%
EPS Revisions
Managers and Directors
Charles R. Kummeth President, Chief Executive Officer & Director
James T. Hippel CFO & Principal Accounting Officer
Robert V. Baumgartner Chairman
Robert Monroe Chief Medical Officer
Brenda Swierenga Furlow Secretary & Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
BIO-TECHNE CORPORATION49.10%18 605
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431